EIF2A and cancer: The ISR itself has received widespread attention in cancer, including CRC, with a variety of outcomes that depend on the activating kinase as well as the downstream pathways induced by phosphorylation of eIF2α (Koromilas, 2015; Schmidt et al, 2020).